Sarepta stock tumbles after Duchenne gene therapy complication
Sarepta Therapeutics stock dropped as much as 13 percent Thursday after news emerged that a child participating in a trial of the company's experimental gene therapy for Duchenne muscular dystrophy experienced a serious health complication.
Sarepta (Nasdaq: SRPT) has been testing a treatment for the rare disease that would insert a functioning gene into patients with the disease, who have a non-working copy of the gene.
The Cambridge biotech's stock quickly dropped Thursday when it was reported…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news
More News: Biotechnology | Children | Gene Therapy | Genetics | Health Management | Muscular Dystrophy | Pharmaceuticals | Rare Diseases | Reflex Sympathetic Dystrophy